Impact Biomedical Stock Today

IBO Stock  USD 0.48  0.01  2.04%   

Performance

Weakest

 
Weak
 
Strong

Odds Of Distress

High

 
High
 
Low
Impact BioMedical is selling at 0.48 as of the 13th of January 2026; that is 2.04% down since the beginning of the trading day. The stock's open price was 0.49. Impact BioMedical has more than 68 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 15th of October 2025 and ending today, the 13th of January 2026. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
16th of September 2024
Category
Healthcare
Classification
Health Care
Impact BioMedical is entity of United States. It is traded as Stock on AMEX exchange. The company has 104.62 M outstanding shares of which 84.17 K shares are currently shorted by investors with about 0.61 days to cover. More on Impact BioMedical

Moving against Impact Stock

  0.77AMGN Amgen IncPairCorr
  0.74CSCO Cisco SystemsPairCorr
  0.7KO Coca Cola Sell-off TrendPairCorr
  0.64JNJ Johnson Johnson Earnings Call Next WeekPairCorr
  0.61MMM 3M Company Earnings Call This WeekPairCorr
  0.61TRV The Travelers Companies Earnings Call This WeekPairCorr

Impact Stock Highlights

Chairman CEOJD Esq
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE AMEX Composite, Health Care, Biotechnology, Biotechnology, Health Care (View all Sectors)
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.0880.1
Fairly Down
Slightly volatile
Total Current Liabilities11.8 M11.3 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total2.2 M3.8 M
Way Down
Slightly volatile
Total Assets14.2 M23.3 M
Way Down
Slightly volatile
Total Current AssetsM2.8 M
Sufficiently Up
Slightly volatile
Debt Levels
Impact BioMedical can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Impact BioMedical's financial leverage. It provides some insight into what part of Impact BioMedical's total assets is financed by creditors.
Liquidity
Impact BioMedical has 8.88 M in debt. Note however, debt could still be an excellent tool for Impact to invest in growth at high rates of return.

Capital Expenditures

0.0
Impact BioMedical (IBO) is traded on AMEX Exchange in USA and employs 2 people. Impact BioMedical is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 50.78 M. Impact BioMedical runs under Biotechnology sector within Health Care industry. The entity has 104.62 M outstanding shares of which 84.17 K shares are currently shorted by investors with about 0.61 days to cover. Impact BioMedical has about 2 M in cash with (5.64 M) of positive cash flow from operations.
Check Impact BioMedical Probability Of Bankruptcy
Ownership Allocation
Impact BioMedical has a total of 104.62 Million outstanding shares. Impact BioMedical retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 89.3 (percent) of Impact BioMedical outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Impact Ownership Details

Impact BioMedical Historical Income Statement

At this time, Impact BioMedical's Income Tax Expense is very stable compared to the past year. As of the 13th of January 2026, Interest Expense is likely to grow to about 299.7 K, while Selling General Administrative is likely to drop about 1 M. View More Fundamentals

Impact Stock Against Markets

Impact BioMedical Corporate Executives

Elected by the shareholders, the Impact BioMedical's board of directors comprises two types of representatives: Impact BioMedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Impact. The board's role is to monitor Impact BioMedical's management team and ensure that shareholders' interests are well served. Impact BioMedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Impact BioMedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Todd CPASecretary CFOProfile
When determining whether Impact BioMedical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Impact BioMedical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Impact Biomedical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Impact Biomedical Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Impact BioMedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
To learn how to invest in Impact Stock, please use our How to Invest in Impact BioMedical guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Impact BioMedical. If investors know Impact will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Impact BioMedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.94)
Revenue Per Share
0.002
Return On Assets
(0.08)
Return On Equity
(3.47)
The market value of Impact BioMedical is measured differently than its book value, which is the value of Impact that is recorded on the company's balance sheet. Investors also form their own opinion of Impact BioMedical's value that differs from its market value or its book value, called intrinsic value, which is Impact BioMedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Impact BioMedical's market value can be influenced by many factors that don't directly affect Impact BioMedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Impact BioMedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Impact BioMedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Impact BioMedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.